Coya Therapeutics (Coya Therapeutics) EV-to-EBIT : -14.12 (As of May. 17, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coya Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Coya Therapeutics's Enterprise Value is $140.08 Mil. Coya Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.92 Mil. Therefore, Coya Therapeutics's EV-to-EBIT for today is -14.12.

The historical rank and industry rank for Coya Therapeutics's EV-to-EBIT or its related term are showing as below:

COYA' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.17 Med: -8.77 Max: -4.52
Current: -14.12

During the past 4 years, the highest EV-to-EBIT of Coya Therapeutics was -4.52. The lowest was -14.17. And the median was -8.77.

COYA's EV-to-EBIT is ranked worse than
100% of 431 companies
in the Biotechnology industry
Industry Median: 10 vs COYA: -14.12

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Coya Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $108.97 Mil. Coya Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.92 Mil. Coya Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -9.10%.

Coya Therapeutics EV-to-EBIT Historical Data

The historical data trend for Coya Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coya Therapeutics EV-to-EBIT Chart

Coya Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-6.64

-10.07

Coya Therapeutics Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial						-2.21	-2.75	-2.49	-10.07	-10.99

Competitive Comparison of Coya Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Coya Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coya Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coya Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Coya Therapeutics's EV-to-EBIT falls into.

Coya Therapeutics EV-to-EBIT Calculation

Coya Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	140.080	/	-9.918
	=	-14.12

Coya Therapeutics's current Enterprise Value is $140.08 Mil.
Coya Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.92 Mil.

Coya Therapeutics (NAS:COYA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Coya Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-9.918	/	108.973944
	=	-9.10 %

Coya Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $108.97 Mil.
Coya Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.92 Mil.

Coya Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Coya Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Coya Therapeutics (Coya Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coya Therapeutics Inc (NAS:COYA) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057

Website

https://www.coyatherapeutics.com

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Executives

Dieter Weinand	director	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Fred Grossman	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Goldstein Dov A Md	director
Adrian Hepner	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
David S Snyder	officer: Chief Financial Officer	ONE SCIENCE COURT, MADISON WI 53711
Hideki Garren	director	C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Anabella Villalobos	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Howard Berman	director, 10 percent owner, officer: Chief Executive Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Ann Lee	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Bertex Llc	10 percent owner	5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057